All In Biotech

Drug Trial Radar · NCT06431893

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)

An Open-Label, Phase 3 Long-Term Extension (LTE) Study To Assess The Safety, Tolerability, And Efficacy Of Treatment With Pegtibatinase In Participants With Classical Homocystinuria (HCU) Due To Cystathionine Beta Synthase Deficiency (ENSEMBLE)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 30, 2024

Primary completion

Aug 2030

Study completion Aug 2030

Sponsor

Lead sponsor
Travere Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 HARMONY are eligible to participate. Participants will be in this clinical study for a minimum of 108 weeks including: a treatment period of up to 104 weeks a 4-week safety follow-up period

Conditions

  • Homocystinuria

Interventions

  • PegtibatinaseDrug

    Pegtibatinase BIW

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent AEsTime frame: Week 1 - Week 108
  2. HypermethioninemiaTime frame: Week 1 - Week 108
  3. HypomethioninemiaTime frame: Week 1 - Week 108
  4. Dietary Protein RescueTime frame: Week 1 - Week 108

Locations

52 sites in 14 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Maine Health Pediatric Specialty Care

    Portland, Maine

  • Uncommon Cures

    Chevy Chase, Maryland

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Science 37 - Virtual Site

    Morrisville, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Utah Health - The University of Utah Primary Children's Hospital

    Salt Lake City, Utah

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Royal Children's Hospital Melbourne

    Parkville, Australia

  • Westmead Hospital

    Westmead, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Belgium

  • Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades

    Paris, France

  • CHRU Hôpitaux de Tours - Hôpital Bretonneau

    Tours, France

  • Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants

    Vandœuvre-lès-Nancy, France

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitätsklinikum Leipzig

    Leipzig, Germany

  • Universitätsklinikum Münster

    Münster, Germany

  • Children's Health Ireland (CHI) at Temple Street

    Dublin, Ireland

  • Ospedale Pediatrico Giovanni XXIII

    Bari, Italy

  • IRCCS Istituto Giannina Gaslini

    Genova, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)

    Milan, Italy

  • Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo

    Monza, Italy

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • SP ZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Instytut Matki i Dziecka

    Warsaw, Poland

  • Instytut Pomnik-Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra

    Coimbra, Portugal

  • Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria

    Lisbon, Portugal

  • Unidade Local de Saúde de São João, EPE - Hospital São João

    Porto, Portugal

  • Hamad General Hospital

    Doha, Qatar

  • Sidra Hospital

    Doha, Qatar

  • King Abdullah International Medical Research Center

    Riyadh, Saudi Arabia

  • King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh

    Riyadh, Saudi Arabia

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.